oral semaglutide 50 mg oasis 1 nejm 2023 obesity New in the September 18, 2025, issue of NEJM: Aspirin for PI3K-Altered Localized Colorectal Cancer (ALASCCA phase 3 trial) https://nej.md/4mpKXNp Orforglipron in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial) https://nej.md/4ngEZ36 oral semaglutide 50 mg obesity

PU was supported by a grant from the Strategic Research Area Epidemiology programme and a Faculty Funded Career Position at Karolinska Institutet

Why Compounded GLP-1 Regulatory Transparency Matters in 2026 If you've made it this far, you already understand more about compounded medications than most people who sign up for telehealth weight loss programs

Quarter Plate (Protein): A portion of grilled chicken, fish, tofu, or legumes

Le-Vel is a real, privately held company founded in 2012 in Frisco, Texas, by Jason Camper and Paul Gravette it is not closing, not under direct FTC enforcement action, and still actively operating in 2026

This blog is for you if you ever ask these questions: Do you wish you could get back in the gym

Long-term urinary health on GLP-1 therapy Most discussions about semaglutide and UTIs focus on the short-term risks